2016 International Scientific Working Group

The mission of the 2016 International Scientific Working Group is to update and revise the 2012 Global Scientific Strategy: Towards an HIV Cure and the accompanying Full Recommendations. 

The large, multi-disciplinary team of approximately 60 representatives globally was formed in November 2014.  A Steering Committee of 7 experts provide oversight and guide the revision of the Global Scientific Strategy which will ultimately serve as a common roadmap for researchers, donors, and other stakeholders to drive funding and research to specifically address the gaps necessary to accelerate the search for a cure for HIV.


Steering Committee

  • Jintanat Ananworanich, US Military HIV Research Programme, USA
  • Françoise Barré-Sinoussi, Institut Pasteur & Inserm, France
  • Monsef Benkirane, Institute of Human Genetics, France
  • Steven Deeks, University of California, San Francisco, USA
  • Sharon Lewin, Doherty Institute for Infection & Immunity, University of Melbourne, Australia
  • Anna Laura Ross, ANRS & IAS, France
  • Joseph Tucker, UNC – Project China, USA

The International Scientific Working Group was divided into six subgroups in line with the priority areas outlined in the document:

  • Molecular biology of HIV latency and shock strategies;
  • Viral reservoirs, immunology of HIV persistence and kill strategies;
  • Models for HIV cure or sustainable remission;
  • Gene/cell therapy;
  • Novel biomarkers and technologies to analyse/quantify HIV reservoirs;
  • Social sciences and health system preparedness.

Subgroup 1: Molecular biology of HIV latency and shock strategies

  • Monsef Benkirane, Institute of Human Genetics, France (co-chair)
  • Eric Cohen, IRCM/Université de Montréal, Canada
  • Gail Henderson, University of North Carolina at Chapel Hill, USA
  • Richard Jefferys, Treatment Action Group, USA
  • David Margolis, University of North Carolina at Chapel Hill, USA (co-chair)
  • Melanie Ott, Gladstone Institutes, University of California, San Francisco, USA
  • Janet Siliciano, John Hopkins University School of Medicine, USA
  • Martin Tolstrup, Aarhus University, Denmark
  • Susana Valente, Scripps Research Institute, USA
  • Jerome Zack, David Geffen School of Medicine at UCLA, USA

Subgroup 2: Viral reservoirs, immunology of HIV persistence and kill strategies

  • Galit Alter, The Ragon Institute of MGH, MIT and Harvard, USA
  • Brigitte Autran, Université Pierre et Marie Curie, France
  • Dan Barouch, The Ragon Institute of MGH, MIT and Harvard, USA
  • Georg Behrens, Hannover Medical School, Germany
  • Zhiwei Chen, The University of Hong Kong, China
  • Giulio Maria Corbelli, Anlaids/EATG, Italy
  • Steven Deeks, University of California, San Francisco, USA (co-chair)
  • Daniel Douek, Vaccine Research Centre, NIAID, NIH, USA (co-chair)
  • Gail Henderson, University of North Carolina at Chapel Hill, USA
  • Timothy Henrich, Brigham & Women’s Hospital, USA
  • Joseph McCune, University of California, San Francisco, USA

Subgroup 3: Models for HIV cure or sustainable remission

  • Jintanat Ananworanich, US Military HIV Research Programme, USA (co-chair)
  • Serge Eholié, Centre Hospitalier Universitaire de Treichville, Côte d'Ivoire
  • Nir Eyal, Harvard University Program in Ethics and Health, USA
  • Sarah Fidler, Imperial College London, United Kingdom
  • Laurindo Garcia, The B-Change Group, Phillippines
  • Victor Garcia Martinez, University of North Carolina at Chapel Hill, USA
  • Jeffrey Lifson, Leidos Biomedical Research, Inc., NCI at Frederick, USA (co-chair)
  • Deborah Persaud, John Hopkins Children’s Center, USA
  • Asier Saez-Cirion, Institut Pasteur, France
  • Guido Silvestri, Yerkes National Primate Research Centre, Emory University, USA

Subgroup 4: Gene/cell therapy

  • Paula Cannon, University of Southern California, USA (co-chair)
  • Marina Cavazzana, Hôpital Necker, France
  • Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, USA
  • Daniel Kuritzkes, Brigham & Women’s Hospital, USA (co-chair)
  • Keymanthri Moodley, CMEL, Stellenbosch University, South Africa
  • Matthew Sharp, HIV Education and Advocacy Consultant, USA
  • Jan van Lunzen, ViiV Healthcare, United Kingdom

Subgroup 5: Novel biomarkers and technologies to analyse/quantify HIV reservoirs

  • Nicolas Chomont, Université de Montréal, Canada
  • Sharon Lewin, Doherty Institute for Infection & Immunity, University of Melbourne, Australia (co-chair)
  • John Mellors, University of Pittsburgh, USA (co-chair)
  • Monique Nijhuis, University Medical Center Utrecht, Netherlands
  • Sarah Palmer, Westmead Millennium Institute, University of Sydney, Australia
  • Douglas Richman, University of California, San Diego, USA
  • Jerome Singh, Nelson R. Mandela School of Medicine, South Africa
  • Jeffrey Taylor, CARE Collaboratory Community Advisory Board, USA

Subgroup 6: Social sciences and health system preparedness

  • Judith Auerbach, University of California, San Francisco, USA
  • Cynthia Grossman, NIMH, NIH, USA
  • Ying-Ru Lo, WHO Regional Office for the Western Pacific, Phillippines (co-chair)
  • Peter Newman, University of Toronto, Canada
  • Moses Supercharger Nsubuga, Joint Clinical Research Centre, Uganda
  • Andrew Phillips, University College London, United Kingdom
  • Bruno Spire, Inserm, France
  • Joseph Tucker, UNC – Project China, USA (co-chair)
  • Rochelle Walensky, Harvard Medical School, USA
  • Ira Wilson, Brown University, USA